🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to evaluate efficacy and safety of brigatinib ...
Status
Completed
Location
Aichi Cancer Center Hospital
Start Date
2018-01-29
Trial ID
NCT03410108
Treatments Being Tested
The main aim of this study is to compare the amount of brigatinib in the bl...
Status
Completed
Location
Celerion, Inc.
Start Date
2023-12-20
Trial ID
NCT06132867
Treatments Being Tested
FDA approved drugs to treat patients with relapsed or refractory anaplastic...
Status
Withdrawn
Location
Fox Chase Cancer Center
Start Date
2018-12-06
Trial ID
NCT03719898
Treatments Being Tested
This is a phase II randomized, open-labelled, non-comparative multicenter s...
Status
Active Not Recruiting
Location
CHU d'Angers
Start Date
2022-05-18
Trial ID
NCT05200481
Treatments Being Tested
This phase Ib trial studies the side effects and best dose of brigatinib an...
Status
Active Not Recruiting
Location
City of Hope Medical Center
Start Date
2020-03-09
Trial ID
NCT04227028
Treatments Being Tested
This is an open-label, phase I-II dose-escalation and expansion study desig...
Status
Recruiting
Location
Institut Gustave Roussy
Start Date
2022-08-18
Trial ID
NCT04925609
Treatments Being Tested
Brigatinib is a medicine that binds to the surface of tumor cells in some c...
Status
Completed
Location
The Oncology Institute of Hope and Innovation
Start Date
2019-04-19
Trial ID
NCT03596866
Treatments Being Tested
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loade...
Status
Active Not Recruiting
Location
CHUV Oncology Department
Start Date
2022-03-22
Trial ID
NCT05195619
This is a multi-arm phase II platform-basket screening study designed to te...
Status
Recruiting
Location
UCLA Medical Center
Start Date
2020-06-20
Trial ID
NCT04374305
Treatments Being Tested
This phase II trial studies how well brigatinib works in treating patients ...
Status
Withdrawn
Location
Ohio State University Comprehensive Cancer Center
Start Date
2019-03-20
Trial ID
NCT03868423